CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 70 enrolled
Drug / intervention
Self Monitoring Lipid Analyzerdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01212159
NCT01212159Phase 4Completed
CompareCT.gov

Telephone Based Management of Hyperlipidemia Utilizing a Self Monitoring Testing Device

Temple University·interventional·Posted Sep 30, 2010·Updated Apr 7, 2026

In Brief

A Phase 4 clinical trial evaluating Self Monitoring Lipid Analyzer for Hyperlipidemia. Completed, enrolled 70 participants across 1 site.

Detailed Summary

The purpose of the study is to demonstrate that systematic self measurement of blood lipids reduces LDL cholesterol more effectively than standard care. The hypothesis is that cholesterol lowering medication adherence will be improved with self monitoring and reporting of frequent blood lipids and the percentage of patients achieving LDL goal will be greater than without home monitoring.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHyperlipidemia
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC

Timeline

Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedSep 30, 2010
Enrollment StartNov 1, 2010
Primary CompletionJul 1, 2015
Study CompletionAug 1, 2015
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 15.8 years ago

Interventions

Self Monitoring Lipid Analyzerdevice

The device is similar to a glucometer- Utilizing a lancet a small amount of blood is collected in a capillary tube and placed on a hand held monitor that records lipid values.